340B Drug Pricing Program
The 340B program accounts for only two percent of the $325 billion in annual drug purchases made in the U.S., or roughly $6.5 billion. Hospitals participating in the 340B program provided $28.4 billion in uncompensated care in 2012; in other words, four times the drug purchase amount.
Yesterday, the Health Resources and Services Administration (HRSA) published its final rule clarifying the Patient Protection and Affordable Care Act (ACA) provision that excludes orphan drugs for purchase under the 340B drug pricing program
Submit Letters to HRSA Outlining Challenges with 340B GPO Notice -- AHA model letter can guide your comments